Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Mizuho Reiterates Outperform Rating on Arcutis Biotherapeutics Inc. (ARQT)
August 16, 2024 2:59 PM EDTMizuho analyst Uy Ear reiterated an Outperform rating and $19.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT)
The analyst comments "For the week ending 08/09/2024, the Zoryve franchise grew 10.5% (vs +4.2% in the prior week) for TRxs and 6.3% (vs +12.4% in the prior week) for... More
